shr2554

Lymphoma

Jiangsu HengRui Medicine Co., Ltd.Phase 1/2Active

CCC

49/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINBLASTINE Intensity Therapeutics, Inc.	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation	Phase 4	BBB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
(+)-VINCRISTINE Beth Israel Deaconess Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

shr2554 is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant

BB

Indicative ·

68 / 100

peripheral T-cell lymphoma, not otherwise specifiedDormant

B

Indicative ·

62 / 100

myelodysplastic syndromeDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.